Focusing on novel modalities and technology advancement, DualityBio has established a variety of antibody drug conjugate platforms and a robust pipeline targeting oncology and autoimmune diseases. At DualityBio, with our proprietary ADC platforms, we are open to collaborate with external partners on multiple fronts, from target identification, drug discovery, co-development to in- and out-licensing of specific assets. We firmly believe the synergy created through collaboration would propel the innovation and business to the higher level.
If you are interested in exploring business opportunities with us, please send your request to BD contact: firstname.lastname@example.org
Flexible and varied collaboration models will enable DualityBio to generate or gain assets with favorable clinical safety and efficacy properties.
Currently, we are looking for strategic partnerships in the following areas:
1) R&D collaboration at pre-clinical stage such as antibody and/or platform collaborations;
2) In-licensing of highly differentiated molecules with significant synergy with DualityBio's pipeline in immuno-oncology and autoimmune diseases;
3) Out-licensing of DualityBio's ADC assets for regional or global partnership;
4) Clincial collaborations for global and/or local combo trials, including IO drug supply and clinical development cost sharing;
5) Co-development and co-commercialization of DualityBio's innovative products for the global market.